ClinicalTrials.gov record
Recruiting Phase 2 Interventional

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

ClinicalTrials.gov ID: NCT06636682

Public ClinicalTrials.gov record NCT06636682. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 23, 2026, 6:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Adaptive, Phase 2, Randomized, Open-label Study of Irradiated Autologous Cellular Vaccine in Men With High-Risk Prostate Cancer Following Prostatectomy

Study identification

NCT ID
NCT06636682
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Cellvax Therapeutics Inc
Industry
Enrollment
100 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Not listed
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 13, 2024
Primary completion
Feb 1, 2027
Completion
May 3, 2027
Last update posted
Oct 20, 2024

2024 – 2027

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
University of Chicago Medicine, High-Risk and Advanced Prostate Cancer Clinic Chicago Illinois 60637 Active, not recruiting
Central Ohio Urology Group Gahanna Ohio 43230 Recruiting
Carolina Urologic Research Center Myrtle Beach South Carolina 29572 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06636682, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 20, 2024 · Synced Apr 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06636682 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →